Sanjay Shukla - 03 Feb 2025 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Role: President and CEO, Director
Signature: /s/ Nancy E. Denyes, attorney-in-fact
Issuer symbol: ATYR
Transactions as of: 03 Feb 2025
Net transactions value: $0
Form type: 4
Filing time: 04 Feb 2025, 18:18:08 UTC
Previous filing: 10 Jan 2025
Next filing: 09 Jan 2026
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATYR	Common Stock	Options Exercise		+10,375	+7.6%		146,923	03 Feb 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATYR	Restricted Stock Unit	Options Exercise	$0	-10,375	-50%	$0.000000	10,375	03 Feb 2025	Common Stock	10,375		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
F2	Restricted stock units convert into common stock on a one-for-one basis.
F3	The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.